|
GB0919431D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
|
PL2571503T3
(pl)
|
2010-05-14 |
2015-06-30 |
Dana Farber Cancer Inst Inc |
Kompozycje i sposoby leczenia nowotworu, choroby zapalnej i innych zaburzeń
|
|
MX354217B
(es)
|
2010-05-14 |
2018-02-19 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
|
CA2799381A1
(en)
|
2010-05-14 |
2011-11-17 |
Dana-Farber Cancer Institute, Inc. |
Male contraceptive compositions and methods of use
|
|
WO2012075456A1
(en)
|
2010-12-02 |
2012-06-07 |
Constellation Pharmaceuticals |
Bromodomain inhibitors and uses thereof
|
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
|
GB201106750D0
(en)
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201106743D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2012151512A2
(en)
|
2011-05-04 |
2012-11-08 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201107325D0
(en)
*
|
2011-05-04 |
2011-06-15 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2012174487A2
(en)
|
2011-06-17 |
2012-12-20 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201114103D0
(en)
*
|
2011-08-17 |
2011-09-28 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
|
WO2013097052A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
|
CA2870931A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Isoindolone derivatives
|
|
WO2013184878A1
(en)
|
2012-06-06 |
2013-12-12 |
Constellation Pharmaceuticals, Inc. |
Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
|
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
|
WO2013185284A1
(en)
|
2012-06-12 |
2013-12-19 |
Abbott Laboratories |
Pyridinone and pyridazinone derivatives
|
|
US9763956B2
(en)
|
2012-06-19 |
2017-09-19 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
|
EP2935253B1
(en)
|
2012-12-21 |
2018-08-01 |
Zenith Epigenetics Ltd. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
US9675697B2
(en)
|
2013-03-11 |
2017-06-13 |
The Regents Of The University Of Michigan |
BET bromodomain inhibitors and therapeutic methods using the same
|
|
SG11201506245QA
(en)
*
|
2013-03-14 |
2015-09-29 |
Glaxosmithkline Ip No 2 Ltd |
2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
|
|
KR20150135359A
(ko)
*
|
2013-03-14 |
2015-12-02 |
컨버진 엘엘씨 |
브로모도메인-함유 단백질의 억제를 위한 방법 및 조성물
|
|
JP6280573B2
(ja)
|
2013-03-14 |
2018-02-14 |
グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ |
ブロモドメイン阻害薬としてのフロピリジン
|
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
ES2909778T3
(es)
|
2013-03-15 |
2022-05-10 |
Incyte Holdings Corp |
Heterociclos tricíclicos como inhibidores de proteína BET para su uso en el tratamiento de una enfermedad proliferativa en combinación con un inhibidor de Janus quinasas
|
|
EA027139B1
(ru)
|
2013-04-26 |
2017-06-30 |
Бейджин, Лтд. |
Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
|
|
WO2015004533A2
(en)
|
2013-06-21 |
2015-01-15 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
WO2015002754A2
(en)
*
|
2013-06-21 |
2015-01-08 |
Zenith Epigenetics Corp. |
Novel bicyclic bromodomain inhibitors
|
|
AR096758A1
(es)
|
2013-06-28 |
2016-02-03 |
Abbvie Inc |
Inhibidores cristalinos de bromodominios
|
|
BR112015032710A2
(pt)
*
|
2013-06-28 |
2017-07-25 |
Abbvie Inc |
inibidores de bromodomínio
|
|
ES2635560T3
(es)
|
2013-07-08 |
2017-10-04 |
Incyte Holdings Corporation |
Heterociclos tricíclicos como inhibidores de la proteína NET
|
|
MX2016001037A
(es)
|
2013-07-25 |
2016-11-10 |
Dana Farber Cancer Inst Inc |
Inhibidores de factores de transcripción y usos.
|
|
WO2015015318A2
(en)
|
2013-07-31 |
2015-02-05 |
Zenith Epigenetics Corp. |
Novel quinazolinones as bromodomain inhibitors
|
|
RS63733B1
(sr)
*
|
2013-10-18 |
2022-12-30 |
Celgene Quanticel Research Inc |
Inhibitori bromodomena
|
|
MX379463B
(es)
|
2013-11-08 |
2025-03-10 |
Dana Farber Cancer Inst Inc |
Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
|
|
SMT202100125T1
(it)
*
|
2013-11-18 |
2021-05-07 |
Forma Therapeutics Inc |
Composizioni di tetraidrochinolina come inibitori di bromodomini bet
|
|
US9422281B2
(en)
|
2013-11-18 |
2016-08-23 |
Forma Therapeutics, Inc. |
Benzopiperazine compositions as BET bromodomain inhibitors
|
|
WO2015081203A1
(en)
|
2013-11-26 |
2015-06-04 |
Incyte Corporation |
Bicyclic heterocycles as bet protein inhibitors
|
|
US9108953B2
(en)
*
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
|
US9315501B2
(en)
|
2013-11-26 |
2016-04-19 |
Incyte Corporation |
Bicyclic heterocycles as BET protein inhibitors
|
|
WO2015095492A1
(en)
|
2013-12-19 |
2015-06-25 |
Incyte Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
MY190835A
(en)
*
|
2014-01-09 |
2022-05-12 |
Orion Corp |
Bicyclic heterrocyclic derivatives as bromodomain inhibitors
|
|
EA038715B1
(ru)
*
|
2014-01-24 |
2021-10-08 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы бромодомена
|
|
EP3099693A4
(en)
|
2014-01-31 |
2017-08-16 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
JP2017504650A
(ja)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
ジアゼパン誘導体およびその使用
|
|
US10150756B2
(en)
|
2014-01-31 |
2018-12-11 |
Dana-Farber Cancer Institute, Inc. |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
|
US9580430B2
(en)
|
2014-02-28 |
2017-02-28 |
The Regents Of The University Of Michigan |
9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
|
|
JP2017506666A
(ja)
|
2014-02-28 |
2017-03-09 |
テンシャ セラピューティクス，インコーポレイテッド |
高インスリン血症に関連した症状の処置
|
|
SG10201809353TA
(en)
|
2014-04-23 |
2018-11-29 |
Incyte Corp |
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
|
|
HUE043441T2
(hu)
|
2014-06-20 |
2019-08-28 |
Constellation Pharmaceuticals Inc |
2-((4S)-6-(4-klórfenil)-l-metil-4H-benzo[c]izoxazolo[4,5-e]azepin-4-il)acetamid kristályos formái
|
|
WO2016022970A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
|
RU2017104897A
(ru)
|
2014-08-08 |
2018-09-10 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Производные диазепана и их применения
|
|
CR20170090A
(es)
*
|
2014-09-12 |
2017-05-08 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Derivados de terahidroquinolina como inhibidores del bromodominio
|
|
WO2016044130A1
(en)
|
2014-09-15 |
2016-03-24 |
Incyte Corporation |
Tricyclic heterocycles for use as bet protein inhibitors
|
|
EP3212654B1
(en)
|
2014-10-27 |
2020-04-08 |
Tensha Therapeutics, Inc. |
Bromodomain inhibitors
|
|
WO2016087936A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridinones as bromodomain inhibitors
|
|
WO2016087942A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridines as bromodomain inhibitors
|
|
US10292968B2
(en)
|
2014-12-11 |
2019-05-21 |
Zenith Epigenetics Ltd. |
Substituted heterocycles as bromodomain inhibitors
|
|
US10231953B2
(en)
|
2014-12-17 |
2019-03-19 |
Zenith Epigenetics Ltd. |
Inhibitors of bromodomains
|
|
EP3262045A1
(en)
|
2015-02-27 |
2018-01-03 |
The Regents of The University of Michigan |
9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
|
|
GB201503720D0
(en)
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
TW201642860A
(zh)
*
|
2015-04-22 |
2016-12-16 |
塞爾基因定量細胞研究公司 |
布羅莫結構域抑制劑
|
|
US10702517B2
(en)
|
2015-04-22 |
2020-07-07 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitor
|
|
WO2016196065A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of cancers to bet inhibitors
|
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
AR105124A1
(es)
|
2015-06-26 |
2017-09-06 |
Tensha Therapeutics Inc |
Tratamiento de carcinoma de la línea media nut
|
|
PE20181088A1
(es)
|
2015-08-10 |
2018-07-09 |
Dana Farber Cancer Inst Inc |
Mecanismo de resistencia a inhibidores de bromodominio bet
|
|
CN108137542B
(zh)
|
2015-09-02 |
2023-10-27 |
葛兰素史克知识产权第二有限公司 |
用作溴结构域抑制剂的吡啶酮二甲酰胺
|
|
RU2018112953A
(ru)
|
2015-09-11 |
2019-10-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Ацетамидтиенотриазолодиазепины и пути их применения
|
|
PE20181287A1
(es)
|
2015-09-11 |
2018-08-07 |
Dana Farber Cancer Inst Inc |
Ciano tienotriazolpirazinas y usos de las mismas
|
|
JP6795588B2
(ja)
|
2015-09-22 |
2020-12-02 |
グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ |
ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
|
|
CA2999379A1
(en)
|
2015-10-05 |
2017-04-13 |
Glaxosmithkline Intellectual Property (No.2) Limited |
2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
|
|
AR106520A1
(es)
|
2015-10-29 |
2018-01-24 |
Incyte Corp |
Forma sólida amorfa de un inhibidor de proteína bet
|
|
US10913752B2
(en)
|
2015-11-25 |
2021-02-09 |
Dana-Farber Cancer Institute, Inc. |
Bivalent bromodomain inhibitors and uses thereof
|
|
ES2882066T3
(es)
|
2016-02-15 |
2021-12-01 |
Univ Michigan Regents |
1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET
|
|
US10759808B2
(en)
|
2016-04-06 |
2020-09-01 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
CN113788818A
(zh)
|
2016-04-06 |
2021-12-14 |
密执安大学评议会 |
Mdm2蛋白质降解剂
|
|
RU2018133500A
(ru)
|
2016-04-07 |
2020-05-12 |
ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед |
Бензо[B]фураны в качестве ингибиторов бромодомена
|
|
ES2840848T3
(es)
|
2016-04-07 |
2021-07-07 |
Glaxosmithkline Ip No 2 Ltd |
Derivados de piridilo como inhibidores de bromodominio
|
|
UA123168C2
(uk)
|
2016-04-12 |
2021-02-24 |
Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган |
Деструктори білка вет
|
|
EP3693369A3
(en)
|
2016-04-15 |
2020-09-09 |
AbbVie Inc. |
Bromodomain inhibitors
|
|
US10844015B2
(en)
|
2016-05-24 |
2020-11-24 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyridine dicarboxamide derivatives as bromodomain inhibitors
|
|
WO2017205536A2
(en)
*
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
TWI830533B
(zh)
|
2016-06-20 |
2024-01-21 |
美商英塞特公司 |
Ｂｅｔ抑制劑之結晶固體形式
|
|
GB201614940D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
GB201614934D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
GB201614939D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
|
CA3036841A1
(en)
|
2016-09-13 |
2018-03-22 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as bet protein degraders
|
|
US11466028B2
(en)
|
2016-09-13 |
2022-10-11 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as BET protein degraders
|
|
CN110099685A
(zh)
*
|
2016-10-20 |
2019-08-06 |
赛尔基因光迪斯研究公司 |
溴结构域抑制剂
|
|
WO2018111805A1
(en)
*
|
2016-12-13 |
2018-06-21 |
St. Jude Children's Research Hospital |
Tetrahydroquinoline-based bromodomain inhibitors
|
|
US11046709B2
(en)
|
2017-02-03 |
2021-06-29 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as BET bromodomain inhibitors
|
|
GB201703282D0
(en)
|
2017-03-01 |
2017-04-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
JOP20190192A1
(ar)
*
|
2017-03-01 |
2019-08-08 |
Glaxosmithkline Ip No 2 Ltd |
مشتقات بيرازول بوصفها مثبطات برومودومين
|
|
GB201716374D0
(en)
*
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
WO2019055444A1
(en)
|
2017-09-13 |
2019-03-21 |
The Regents Of The University Of Michigan |
DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
|
|
GB201716369D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201716392D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201814167D0
(en)
|
2018-08-31 |
2018-10-17 |
Glaxosmithkline Ip No 2 Ltd |
Compounds
|
|
TWI882964B
(zh)
|
2018-09-13 |
2025-05-11 |
大陸商恒翼生物醫藥（上海）股份有限公司 |
Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法
|
|
TWI816880B
(zh)
*
|
2018-09-13 |
2023-10-01 |
大陸商恒翼生物醫藥（上海）股份有限公司 |
治療前列腺癌之組合療法
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
US20250382308A1
(en)
|
2022-04-19 |
2025-12-18 |
Nuevolution A/S |
Compounds active towards bromodomains
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|